Related references
Note: Only part of the references are listed.Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
PD-L1 receptor expression in vulvar carcinomas is HPV-independent
M. Choschzick et al.
VIRCHOWS ARCHIV (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Review of Immune Therapies Targeting Ovarian Cancer
Cong (Ava) Fan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Review of checkpoint immunotherapy for the management of non-small cell lung cancer
Shine Raju et al.
IMMUNOTARGETS AND THERAPY (2018)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PD-L1 expression on immune cells is a favorable prognostic factor for vulvar squamous cell carcinoma patients
Jacek J. Sznurkowski et al.
ONCOTARGET (2017)
Current state of immunotherapy for non-small cell lung cancer
Jyoti Malhotra et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2017)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim et al.
CANCER RESEARCH AND TREATMENT (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian et al.
NATURE REVIEWS CANCER (2016)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
Systemic treatment of vulvar cancer
Sven Mahner et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Upregulation of PD-LI and APEI is associated with tumorigenesis and poor prognosis of gastric cancer
Yi Qing et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2015)
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
Francois Bertucci et al.
ONCOTARGET (2015)
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Marcella Callea et al.
CANCER IMMUNOLOGY RESEARCH (2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Lars Henning Schmidt et al.
PLOS ONE (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma
Marta del Pino et al.
HISTOPATHOLOGY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Estimation of groin recurrence risk in patients with squamous cell vulvar carcinoma by the assessment of marker gene expression in the lymph nodes
Magdalena Kowalewska et al.
BMC CANCER (2012)
Prevalence of Human Papillomavirus Types in Invasive Vulvar Cancers and Vulvar Intraepithelial Neoplasia 3 in the United States Before Vaccine Introduction
Julia W. Gargano et al.
JOURNAL OF LOWER GENITAL TRACT DISEASE (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Chronic inflammation in cancer development
Gabriele Multhoff et al.
FRONTIERS IN IMMUNOLOGY (2012)
New aspects of vulvar cancer: Changes in localization and age of onset
Monika Hampl et al.
GYNECOLOGIC ONCOLOGY (2008)
Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva
Francesco Raspagliesi et al.
GYNECOLOGIC ONCOLOGY (2006)
B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis
MM Mazanet et al.
JOURNAL OF IMMUNOLOGY (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
HD Dong et al.
NATURE MEDICINE (2002)
Share Paper
